Table 1 Molecular and clinical characteristics of patients with essential thrombocythemia (ET)
Variables | CALR mutation (n = 22) | JAK2 V617F mutation (n = 28) | Triple Negative (n = 14) | p-value |
|---|---|---|---|---|
Males (%) | 15 (68.2) | 12 (42.9) | 6 (42.9) | 0.395 |
Age, Median (Range) | 35 (28–73) | 57.5 (34.0–85.0) | 35 (18–75) | 0.001** |
Risk Group: | ||||
 Low (%) | 15 | 14 | 2 | 0.043* |
 High (%) | 7 | 14 | 12 |  |
Haemoglobin (g/dL), Median (Range) | 10.2 (9.2–11.1) | 12.3 (10.5–15.1) | 12.8 (11.7–16.8) | 0.641 |
TLC ×109/L, Median (Range) | 9.3 (5.11–16.7) | 9.5 (4.7–147) | 11.2 (2.3147) | 0.061 |
Platelet ×109/L, Median (Range) | 1003.0 (462–2305) | 928.5 (92–1883) | 1064.5 (382–1841) | 0.373 |
Reticulin Fibrosis | ||||
MF 0 | 12 (54.5) | 20 (71.4) | 10 (71.4) | Â |
MF 1 | 7 (318) | 8 (28.6) | 4 (28.6) | 0.052 |
MF 2 | 3 (13.6) | 0 | 0 | Â |
Constitutional symptoms (%) | 13 (59.1) | 13 (46.4) | 4 (28.6) | Â |
Thromboembolic events (%) | 3 (13.6) | 4 (14.3) | 2(14.3) | 0.033* |